Current HIV/AIDS Reports

, Volume 4, Issue 1, pp 42–47

Role of immune activation in HIV pathogenesis

Article

Abstract

T-cell activation has long been considered a central mediator of HIV pathogenesis. High T-cell activation levels predict more rapid disease progression in untreated patients and decreased treatment-mediated CD4+ T-cell gains during antiretroviral therapy, independent of plasma HIV RNA levels, and may be the primary feature distinguishing pathogenic from nonpathogenic primate models of HIV infection. Studies in animal models and individuals with HIV infection continue to enhance our understanding of how T-cell activation causes immunodeficiency during HIV infection. The goal of these studies is to identify specific mechanisms that can be targeted by novel immune-based therapies for patients who have thus far been unable to recover normal immune function despite years of antiretroviral therapy. Although most immune-based therapies targeting T-cell activation have been unsuccessful to date, recent scientific developments have focused attention on specific pathways that may be exploited by future generations of immune-based therapies.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Finkel TH, Tudor-Williams G, Banda NK, et al.: Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV-and SIV-infected lymph nodes. Nat Med 1995, 1:129–134.PubMedCrossRefGoogle Scholar
  2. 2.
    Groux H, Torpier G, Monte D, et al.: Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992, 175:331–340.PubMedCrossRefGoogle Scholar
  3. 3.
    Meyaard L, Otto SA, Jonker RR, et al.: Programmed death of T cells in HIV-1 infection. Science 1992, 257:217–219.PubMedCrossRefGoogle Scholar
  4. 4.
    Silvestri G, Sodora DL, Koup RA, et al.: Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003, 18:441–452.PubMedCrossRefGoogle Scholar
  5. 5.
    Harper ME, Marselle LM, Gallo RC, Wong-Staal F: Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. Proc Natl Acad Sci U S A 1986, 83:772–776.PubMedCrossRefGoogle Scholar
  6. 6.
    Ascher MS, Sheppard HW: AIDS as immune system activation: a model for pathogenesis. Clin Exp Immunol 1988, 73:165–167.PubMedGoogle Scholar
  7. 7.
    Papagno L, Spina CA, Marchant A, et al.: Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2004, 2:E20.PubMedCrossRefGoogle Scholar
  8. 8.
    Doisne JM, Urrutia A, Lacabaratz-Porret C, et al.: CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol 2004, 173:2410–248.PubMedGoogle Scholar
  9. 9.
    Grossman Z, Meier-Schellersheim M, Sousa AE, et al.: CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? Nat Med 2002, 8:319–323.PubMedCrossRefGoogle Scholar
  10. 10.
    Hazenberg MD, Otto SA, van Benthem BH, et al.: Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003, 17:1881–1888.PubMedCrossRefGoogle Scholar
  11. 11.
    Tesselaar K, Arens R, van Schijndel GM, et al.: Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat Immunol 2003, 4:49–54.PubMedCrossRefGoogle Scholar
  12. 12.
    Suntharalingam G, Perry MR, Ward S, et al.: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006, 355:1018–1028.PubMedCrossRefGoogle Scholar
  13. 13.
    Brenchley JM, Schacker TW, Ruff LE, et al.: CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004, 200:749–759.PubMedCrossRefGoogle Scholar
  14. 14.
    Guadalupe M, Reay E, Sankaran S, et al.: Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003, 77:11708–11717.PubMedCrossRefGoogle Scholar
  15. 15.
    Mehandru S, Poles MA, Tenner-Racz K, et al.: Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004, 200:761–770.PubMedCrossRefGoogle Scholar
  16. 16.
    Giorgi JV, Majchrowicz MA, Johnson TD, et al.: Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS 1998, 12:1833–1844.PubMedCrossRefGoogle Scholar
  17. 17.
    Bleul CC, Wu L, Hoxie JA, et al.: The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A 1997, 94:1925–1930.PubMedCrossRefGoogle Scholar
  18. 18.
    Wu L, Paxton WA, Kassam N, et al.: CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997, 185:1681–1691.PubMedCrossRefGoogle Scholar
  19. 19.
    Shattock RJ, Rizzardi GP, Hayes P, Griffin GE: Engagement of adhesion molecules (CD18, CD11a, CD45, CD44, and CD58) enhances human immunodeficiency virus type 1 replication in monocytic cells through a tumor necrosis factor-modulated pathway. J Infect Dis 1996, 174:54–62.PubMedGoogle Scholar
  20. 20.
    Calman AF, Busch MP, Vyas GN, et al.: Transcription and replication of human immunodeficiency virus-1 in B lymphocytes in vitro. AIDS 1988, 2:185–193.PubMedGoogle Scholar
  21. 21.
    Kawakami K, Scheidereit C, Roeder RG: Identification and purification of a human immunoglobulin-enhancer-binding protein (NF-kappa B) that activates transcription from a human immunodeficiency virus type 1 promoter in vitro. Proc Natl Acad Sci U S A 1988, 85:4700–4704.PubMedCrossRefGoogle Scholar
  22. 22.
    Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ: Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 2006, 12:289–295.PubMedCrossRefGoogle Scholar
  23. 23.
    Schacker TW, Nguyen PL, Beilman GJ, et al.: Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest 2002, 110:1133–1139.PubMedCrossRefGoogle Scholar
  24. 24.
    Schacker TW, Reilly C, Beilman GJ, et al.: Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated change in peripheral CD4 cell count. AIDS 2005, 19:2169–2171.PubMedCrossRefGoogle Scholar
  25. 25.
    Schacker TW, Nguyen PL, Martinez E, et al.: Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. J Infect Dis 2002, 186:1092–1097.PubMedCrossRefGoogle Scholar
  26. 26.
    Merrill JE, Koyanagi Y, Chen IS: Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. J Virol 1989, 63:4404–4408.PubMedGoogle Scholar
  27. 27.
    Rieckmann P, Poli G, Fox CH, et al.: Recombinant gp120 specifically enhances tumor necrosis factor-alpha production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors. J Immunol 1991, 147:2922–2927.PubMedGoogle Scholar
  28. 28.
    Swingler S, Mann A, Jacque J, et al.: HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med 1999, 5:997–1003.PubMedCrossRefGoogle Scholar
  29. 29.
    Schindler M, Munch J, Kutsch O, et al.: Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 2006, 125:1055–1067.PubMedCrossRefGoogle Scholar
  30. 30.
    Eggena MP, Barugahare B, Jones N, et al.: Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol 2005, 174:4407–4414.PubMedGoogle Scholar
  31. 31.
    Matsuyama T, Kobayashi N, Yamamoto N: Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 1991, 5:1405–1417.PubMedCrossRefGoogle Scholar
  32. 32.
    Brenchley JM, Price DA, Douck DC: HIV disease: fallout from a mucosal catastrophe? Nat Immunol 2006, 7:235–239.PubMedCrossRefGoogle Scholar
  33. 33.
    Lenkei R, Andersson B: High correlations of anti-CMV titers with lymphocyte activation status and CD57 antibody-binding capacity as estimated with three-color, quantitative flow cytometry in blood donors. Clin Immunol Immunopathol 1995, 77:131–138.PubMedCrossRefGoogle Scholar
  34. 34.
    Valdez H, Anthony D, Farukhi F, et al.: Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients. AIDS 2000, 14:2239–2246.PubMedCrossRefGoogle Scholar
  35. 35.
    Schacker T, Zeh J, Hu H, et al.: Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002, 186:1718–1725.PubMedCrossRefGoogle Scholar
  36. 36.
    Giorgi JV, Hultin LE, McKeating JA, et al.: Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999, 179:859–870.PubMedCrossRefGoogle Scholar
  37. 37.
    Giorgi JV, Lyles RH, Matud JL, et al.: Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002, 29:346–355.PubMedGoogle Scholar
  38. 38.
    Deeks SG, Kitchen CM, Liu L, et al.: Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004, 104:942–947.PubMedCrossRefGoogle Scholar
  39. 39.
    Hunt PW, Martin JN, Sinclair E, et al.: T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003, 187:1534–1543.PubMedCrossRefGoogle Scholar
  40. 40.
    Smith K, Aga E, Bosch RJ, et al.: Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. AIDS 2004, 18:1953–1956.PubMedCrossRefGoogle Scholar
  41. 41.
    Goicoechea M, Smith DM, Liu L, et al.: Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis 2006, 194:29–37.PubMedCrossRefGoogle Scholar
  42. 42.
    Benito JM, Lopez M, Lozano S, et al.: CD4+ T cell recovery beyond the first year of complete suppression of viral replication during highly active antiretroviral therapy is not influenced by CD8+ T cell activation. J Infect Dis 2005, 192:2142–2146.PubMedCrossRefGoogle Scholar
  43. 43.
    Miller V, Phillips AN, Clotet B, et al.: Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002, 186:189–197.PubMedCrossRefGoogle Scholar
  44. 44.
    Pitrak DL, Bolanos J, Hershow R, Novak RM: Discordant CD4 T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex-vivo rates of apoptosis. AIDS 2001, 15:1317–1319.PubMedCrossRefGoogle Scholar
  45. 45.
    Deeks SG, Hoh R, Grant RM, et al.: CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis 2002, 185:315–323.PubMedCrossRefGoogle Scholar
  46. 46.
    Sloand EM, Kumar PN, Kim S, et al.: Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 1999, 94:1021–1027.PubMedGoogle Scholar
  47. 47.
    Hunt PW, Deeks SG, Bangsberg DR, et al.: The independent effect of drug resistance on T cell activation in HIV infection. AIDS 2006, 20:691–699.PubMedCrossRefGoogle Scholar
  48. 48.
    Wyma DJ, Jiang J, Shi J, et al.: Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail. J Virol 2004, 78:3429–3435.PubMedCrossRefGoogle Scholar
  49. 49.
    Rizzardi GP, Harari A, Capiluppi B, et al.: Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002, 109:681–688.PubMedCrossRefGoogle Scholar
  50. 50.
    Kaufmann GR, Bloch M, Finlayson R, et al.: The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002, 16:359–367.PubMedCrossRefGoogle Scholar
  51. 51.
    Valdez H, Connick E, Smith KY, et al.: Limited immune restoration after 3 years’ suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002 16:1859–1866.PubMedCrossRefGoogle Scholar
  52. 52.
    Davey RT Jr, Chaitt DG, Albert JM, et al.: A randomized trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 1999, 179:849–858.PubMedCrossRefGoogle Scholar
  53. 53.
    Davey RT Jr, Murphy RL, Graziano FM, et al.: Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA 2000, 284:183–189.PubMedCrossRefGoogle Scholar
  54. 54.
    Kovacs JA, Vogel S, Albert JM, et al.: Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996, 335:1350–1356.PubMedCrossRefGoogle Scholar
  55. 55.
    Sereti I, Anthony KB, Martinez-Wilson H, et al.: IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 2004, 104:775–780.PubMedCrossRefGoogle Scholar
  56. 56.
    Sereti I, Imamichi H, Natarajan V, et al.: In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest 2005, 115:1839–1847.PubMedCrossRefGoogle Scholar
  57. 57.
    McComsey GA, Whalen CC, Mawhorter SD, et al.: Placebo-controlled trial of prednisone in advanced HIV-1 infection. AIDS 2001, 15:321–327.PubMedCrossRefGoogle Scholar
  58. 58.
    Havlir DV, Gilbert PB, Bennett K, et al.: Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS 2001, 15:1379–1388.PubMedCrossRefGoogle Scholar
  59. 59.
    Calabrese LH, Lederman MM, Spritzler J, et al.: Placebo-controlled trial of cyclosporine-A in HIV-1 disease: implications for solid organ transplantation. J Acquir Immune Defic Syndr 2002, 29:356–362.PubMedGoogle Scholar
  60. 60.
    Sankatsing SU, Jurriaans S, van Swieten P, et al.: Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS 2004, 18:1925–1931.PubMedCrossRefGoogle Scholar
  61. 61.
    Lederman MM, Smeaton L, Smith KY, et al.: Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. J Infect Dis 2006, 194:1677–1685.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Positive Health ProgramSan Francisco General HospitalSan FranciscoUSA

Personalised recommendations